Decreased adiponectin levels promote the progression to myeloma from the pre-myeloma stage, because a low adiponectin level is not sufficient to properly inhibit acetyl-CoA-carboxylase, a key enzyme of lipid synthesis in tumour cells[124]. Here, ADIPOQ is linked to neoplasm.